VRDN
Viridian Therapeutics Inc

9,405
Mkt Cap
$2.74B
Volume
1.67M
52W High
$29.58
52W Low
$9.90
PE Ratio
-8.12
VRDN Fundamentals
Price
$29.47
Prev Close
$28.68
Open
$29.10
50D MA
$22.79
Beta
1.07
Avg. Volume
1.38M
EPS (Annual)
-$3.07
P/B
7.51
Rev/Employee
$2,111.89
Loading...
Loading...
News
all
press releases
Persistent Asset Partners Ltd Sells 9,179 Shares of Viridian Therapeutics, Inc. $VRDN
Persistent Asset Partners Ltd cut its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 24.7% during the 2nd quarter, according to the company in its most recent disclosure with...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Candriam S.C.A. Has $12.06 Million Stock Position in Viridian Therapeutics, Inc. $VRDN
Candriam S.C.A. lowered its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 2.1% in the second quarter, according to the company in its most recent disclosure with...
MarketBeat·4d ago
News Placeholder
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 12-Month High - Should You Buy?
Viridian Therapeutics (NASDAQ:VRDN) Hits New 52-Week High - Time to Buy...
MarketBeat·7d ago
News Placeholder
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have received an average recommendation of "Moderate Buy" from the eleven research firms that are presently covering the company...
MarketBeat·10d ago
News Placeholder
What is Leerink Partnrs' Forecast for VRDN FY2025 Earnings?
Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities researchers at Leerink Partnrs boosted their FY2025 earnings estimates for shares of Viridian Therapeutics in a report issued on...
MarketBeat·11d ago
News Placeholder
What is Lifesci Capital's Estimate for VRDN FY2025 Earnings?
Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities researchers at Lifesci Capital boosted their FY2025 earnings estimates for shares of Viridian Therapeutics in a report issued on...
MarketBeat·11d ago
News Placeholder
Research Analysts Offer Predictions for VRDN FY2029 Earnings
Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Research analysts at Leerink Partnrs cut their FY2029 earnings per share (EPS) estimates for shares of Viridian Therapeutics in a research...
MarketBeat·12d ago
News Placeholder
Viridian Therapeutics (NASDAQ:VRDN) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen raised shares of Viridian Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·13d ago
News Placeholder
Best Biotech Stocks To Consider - November 6th
Moderna, Vertex Pharmaceuticals, Danaher, Iovance Biotherapeutics, Recursion Pharmaceuticals, argenex, and Viridian Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's...
MarketBeat·13d ago
News Placeholder
Royal Bank Of Canada Forecasts Strong Price Appreciation for Viridian Therapeutics (NASDAQ:VRDN) Stock
Royal Bank Of Canada boosted their price target on shares of Viridian Therapeutics from $41.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday...
MarketBeat·13d ago

Latest VRDN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.